Sanara MedTechSMTI -4.03%72 Days Payable is 77.31 as of Mar. 2026, which is 16% below its 10-year median of 92.13. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.54 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Sanara MedTech ranks better than 55.72% on this metric.
The historical rank and industry rank for Sanara MedTech's Days Payable or its related term are showing as below:
SMTI'
s Days Payable Range Over the Past 10 Years
Min: 57.98 Med: 92.13 Max: 171.72
Current: 77.26
During the past 13 years, Sanara MedTech's highest Days Payable was 171.72. The lowest was 57.98. And the median was 92.13.
SMTI's Days Payable is ranked better than 55.72% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs SMTI: 77.26
Sanara MedTech's Days Payable
declined
from Mar. 2025 (91.20) to Mar. 2026 (77.31).
It may suggest that Sanara MedTechaccelerated paying its suppliers.
Sanara MedTech Days Payable Related Terms
Sanara MedTech Days Payable Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sanara MedTech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Days Payable distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sanara MedTech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanara MedTech (SMTI) has a Days Payable of 77.31 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sanara MedTech and its competitors. This is 16% below median its historical median of 92.13. Over the past decade, Sanara MedTech's Days Payable has ranged from 57.98 to 171.72. According to the industry distribution chart, Sanara MedTech ranks #352 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 44.3%.
Is Sanara MedTech's Days Payable too high?
Sanara MedTech's current Days Payable of 77.31 is 16% below median its 10-year median of 92.13. Over the past 10 years, this metric has ranged from a low of 57.98 to a high of 171.72. The Medical Devices & Instruments industry median Days Payable is 68.07. Sanara MedTech's value of 77.31 is 13.6% above this industry median. Based on the distribution chart, Sanara MedTech ranks #352 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Days Payable compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #352 out of 795 companies for Days Payable. This puts Sanara MedTech in the upper half of its industry. The industry median Days Payable is 68.07. Sanara MedTech's value of 77.31 is 13.6% above this benchmark. Historically, Sanara MedTech's own Days Payable has ranged from 57.98 to 171.72 over the past decade. While the company's 10-year median is 92.13 vs. the industry median of 68.07, Sanara MedTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current Days Payable of 77.31 is 13.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current Days Payable is 77.31, which is 16% below median its own 10-year median of 92.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.54, compared to a current price of $23.59 — trading 48.2% below its estimated fair value. The current Days Payable is 77.31, which is 16% below median its 10-year median of 92.13 and 13.6% above the Medical Devices & Instruments industry median of 68.07. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Days Payable is 77.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $23.59 is trading 48.2% below its estimated GF Value™ of $45.54.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
Days Payable: 77.31 (16% below median its 10-year median of 92.13)
GF Value™: $45.54 vs. price of $23.59 (48.2% below fair value)
Industry Position: 13.6% above the Medical Devices & Instruments median (#352 of 795)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score
Get the complete analysis for SMTI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
